

Leading Age Oklahoma
Annual Conference
March 7, 2018

Trends in Pharmacy under the Requirements of Participations

William M. Vaughan RN, BSN
Vice President, Education and Clinical Affairs
Remedi SeniorCare

1 | © 2015 Remedi SeniorCare™



DISCLOSURE / CONTACT INFO

Disclosure

- Remedi SeniorCare
- Institute for Safe Medication Practices (ISMP)

Contact

- william.vaughan@remedirx.com

2 | © 2015 Remedi SeniorCare™



Institute for Safe Medication Practices

A Nonprofit Organization Educating the Healthcare Community and Consumers About Safe Medication Practices

"Welcome to the ISMP *Long-Term Care Advise-ERR*, a medication safety newsletter designed specifically to meet the needs of administrators, nursing directors, and nurses who transcribe medication orders, administer medications, monitor the effects of medications on residents, and/or supervise those who carry out these important tasks."

<http://www.ismp.org/Newsletters/longtermcare/default.aspx>

3 | © 2015 Remedi SeniorCare™



OBJECTIVES

- 1) Discuss the impact that the reporting of all drug irregularities to the Medical Director has had on medication safety.
- 2) List which medications surveyors have identified, through deficiency data, as meeting the regulatory definition of a psychotropic drug.
- 3) Explain how limits on PRN orders for psychotropic drugs has impacted resident care.
- 4) Describe trends and patterns regarding antibiotic stewardship which have resulted in deficiency citations.

4 | © 2015 Remedi SeniorCare™



DATA SOURCE

- 1) Data portal
<https://data.medicare.gov/>
- 2) Aggregate health deficiencies cited in federally certified nursing homes
<https://data.medicare.gov/Nursing-Home-Compare/Health-Deficiencies/nptf-b6wt>
- 3) Redacted deficiencies for specific nursing homes
<https://www.medicare.gov/nursinghomecompare/search.html>

➤ Accessed February 14 and March 4, 2018

5 | © 2015 Remedi SeniorCare™



DRUG IRREGULARITY → MEDICAL DIRECTOR

In effect x 15 months, your experience?

- Clinical intervention
- Practitioner oversight
- Data aggregation / analysis
- QAPI
- P & P
- Follow-up
- Barriers




6 | © 2015 Remedi SeniorCare™



**DRUG IRREGULARITY → MEDICAL DIRECTOR
F 428 (OLD) / F 756 (NEW)**


Deficiency Data


7 | © 2015 Remedi SeniorCare™ 

PSYCHOTROPIC DRUG

“ ... **any** drug that affects brain activities associated with mental processes and behavior.”


- Anti-psychotic
- Anti-depressant
- Anti-anxiety
- Hypnotic
- ????????



8 | © 2015 Remedi SeniorCare™ 


PSYCHOTROPIC DRUG (F 758)


Deficiency Data

9 | © 2015 Remedi SeniorCare™ 

PRN LIMITS - PSYCHOTROPIC DRUG


- Prescriber push-back
- Drug class substitution
- Change to routine v PRN
- Documentation
- Delay in treatment
- Pharmacy operational assistance



10 | © 2015 Remedi SeniorCare™ 


**PRN LIMITS - PSYCHOTROPIC DRUG
(F 758)**


Deficiency Data

11 | © 2015 Remedi SeniorCare™ 

ANTIBIOTIC STEWARDSHIP

- Protocols
- Monitoring
- Diagnostic criteria
- Drug
- Dose
- Duration
- Data
- Regulation versus best practice
 - CDC core elements



12 | © 2015 Remedi SeniorCare™ 

ANTIBIOTIC STEWARDSHIP (F 881)

Deficiency Data

13 | © 2015 Remedi SeniorCare™



F 552: Planning and Implementing Care

The resident has the right to be informed of, and participate in, his or her treatment, including:

- The right to be fully informed in language that he or she can understand of his or her total health status, including but not limited to, his or her medical condition.
- The right to be informed, in advance, of the care to be furnished and the type of care giver or professional that will furnish care.
- The right to be informed in advance, by the physician or other practitioner or professional, of the risks and benefits of proposed care, of treatment and treatment alternatives or treatment options and to choose the alternative or option he or she prefers.



14 | © 2015 Remedi SeniorCare™



Thank
You